10-K: Unicycive Therapeutics Reports 2023 Annual Results, Highlights Progress in Kidney Disease Therapies

Unicycive Therapeutics' 2023 annual report details financial losses alongside advancements in clinical trials for their kidney disease treatments, Oxylanthanum Carbonate and UNI 494.

Summary

• Unicycive Therapeutics, a biotechnology company, is focused on developing treatments for kidney disease, with two main programs: Oxylanthanum Carbonate for hyperphosphatemia in chronic kidney disease patients on dialysis, and UNI 494 for acute kidney injury.
• The company reported a net loss of $30.5 million for 2023, compared to a net loss of $18.1 million in 2022, and an accumulated deficit of $64.5 million as of December 31, 2023.
• They have completed a bioequivalence study for Oxylanthanum Carbonate, showing it is equivalent to Fosrenol, and initiated a tolerability study in chronic kidney disease patients on dialysis, with topline data expected by the end of Q2 2024.
• For UNI 494, a Phase 1 study in healthy volunteers was initiated and is expected to be completed in the second half of 2024, and the company plans to file an IND application for a Phase 2 trial in Q4 2024.
• The company has global commercial rights to Oxylanthanum Carbonate and has entered into licensing agreements with Lees Pharmaceutical for China and other Asian markets, and with Lotus Pharmaceutical for South Korea.
• The worldwide market for hyperphosphatemia agents is estimated at ~$2.5 billion, with the U.S. market making up over $1 billion of that total.
• The company estimates the potential market for UNI-494 in delayed graft function (DGF) at $1 billion and in acute kidney injury (AKI) at $3 billion in the U.S. alone.

Sentiment

Score: 5

Explanation: The document presents a mixed sentiment. While there is progress in clinical trials and licensing agreements, the significant financial losses and dependence on future capital raises temper the positive aspects. The company is making progress but faces significant challenges.

Positives

• Oxylanthanum Carbonate has shown bioequivalence to Fosrenol, a currently approved drug, which could streamline the approval process.
• The company has secured licensing agreements for Oxylanthanum Carbonate in key Asian markets, providing potential revenue streams.
• UNI 494 has received orphan drug designation from the FDA for the prevention of DGF, which provides tax credits, user fee exemptions, and potential market exclusivity.
• The company has completed a Phase 1 study for UNI 494 and is progressing towards a Phase 2 trial.
• The company has a clear regulatory pathway for Oxylanthanum Carbonate through the 505(b)(2) pathway.
• The company has secured $50 million in funding in March 2024 to support operations.

Negatives

• The company reported a significant net loss of $30.5 million for 2023, and an accumulated deficit of $64.5 million.
• The company has not generated any product revenue to date and is dependent on future capital raises.
• The company is reliant on third-party manufacturers and CROs, which introduces risks of delays and quality issues.
• The company faces significant competition in the hyperphosphatemia and AKI markets.
• The company may face challenges in obtaining adequate coverage and reimbursement for its products.
• The company has identified a material weakness in its internal control over financial reporting.

Risks

• The company has a limited operating history and has incurred significant losses since inception.
• The company's future profitability is uncertain, and it may not be able to achieve profitability.
• The company will need to raise substantial additional capital to fund its operations and the development and commercialization of its product candidates.
• The company's product candidates may not receive regulatory approval, or if approved, may not achieve market acceptance.
• The company relies on third parties for manufacturing and clinical trials, which could lead to delays or quality issues.
• The company faces significant competition from other pharmaceutical and biotechnology companies.
• The company's intellectual property may not be sufficient to protect its product candidates from competition.
• The company's common stock may be delisted from The Nasdaq Capital Market if it fails to comply with continued listing standards.
• The company may be subject to product liability lawsuits, which could cause it to incur substantial liabilities.
• The company may be adversely affected by the coronavirus-type pandemic.

Future Outlook

The company plans to submit an NDA for Oxylanthanum Carbonate soon after completing the tolerability study, and to file an IND application for a Phase 2 trial of UNI 494 in Q4 2024. They will continue to seek licensing partners for Oxylanthanum Carbonate in other territories outside the U.S.

Management Comments

• The company believes that its management team's broad network, expertise in the biopharmaceutical industry, and successful track record gives it an advantage in identifying and bringing assets into the company.
• Executive management of the company has considerable product launch experience in the nephrology space with specific working knowledge of the hyperphosphatemia market.
• The company believes that the timing of the change in federal regulation to include phosphate lowering drugs into the dialysis bundle in 2025 coincides favorably with their anticipated launch timing of Oxylanthanum Carbonate.

Industry Context

The company operates in a highly competitive and regulated industry, facing competition from large pharmaceutical companies and academic institutions. The hyperphosphatemia market is estimated at ~$2.5 billion globally, and the company is positioning Oxylanthanum Carbonate as a potential competitor to existing phosphate binders. The company is also targeting the acute kidney injury market, which has a high unmet medical need.

Comparison to Industry Standards

• The document compares Oxylanthanum Carbonate to Fosrenol, a currently approved lanthanum-based phosphate binder, demonstrating bioequivalence in a clinical study.
• The document also compares Oxylanthanum Carbonate to Xphozah (tenapanor), a new hyperphosphatemia treatment, highlighting Oxylanthanum Carbonate's expected greater treatment effect and broader indication.
• The document notes that 75% of U.S. dialysis patients fail to achieve serum phosphorus target levels with currently available phosphate binders, underscoring the need for new treatment options.
• The document mentions that current phosphate binders often result in poor adherence due to large pill sizes and high pill counts, which Oxylanthanum Carbonate aims to address with its novel nanoparticle technology.
• The document states that the rate of DGF is 20 30.4% for DBD (donor brain death) organs and 45 55.1% for DCD (donor circulatory death) organs, highlighting the need for effective treatments like UNI-494.

Related Party Transactions

• The company has a service agreement with Globavir Biosciences, Inc., a related party, for administrative and consulting services.

Stakeholder Impact

• Shareholders face the risk of dilution from future capital raises and potential loss of investment if the company is not successful.
• Employees may be affected by the company's financial performance and ability to secure funding.
• Patients with kidney disease may benefit from the development of new treatment options.
• The company's suppliers and partners may be affected by its financial performance and ability to meet its obligations.

Next Steps

• Complete the tolerability study of Oxylanthanum Carbonate in chronic kidney disease patients on dialysis.
• Submit the NDA for Oxylanthanum Carbonate to the FDA.
• Complete the Phase 1 study for UNI 494 in healthy volunteers.
• File an IND application for a Phase 2 proof-of-concept trial for UNI 494 in DGF.
• Continue to seek licensing partners for Oxylanthanum Carbonate in other territories outside the U.S.

Key Dates

Keywords

Oxylanthanum Carbonate, UNI 494, hyperphosphatemia, acute kidney injury, chronic kidney disease, phosphate binder, clinical trials, FDA approval, licensing agreements, biotechnology